Manus

Accelerating the Transition to BioAlternatives

[Manus @manusbio]

America’s essential medicine supply chains depend on domestic biomanufacturing capacity.

Manus recently welcomed elected officials and representatives from @HHSGov Administration for Strategic Preparedness and Response (@ASPRgov) to break ground on a domestic biomanufacturing facility for artemisinin – the starting material for the world’s frontline antimalarial therapy – at its Augusta BioFacility.

The expansion brings cGMP capabilities to the site, combining biomanufacturing and flow chemistry under one roof to onshore U.S. production of critical essential medicines.

Thank you, @WFXGFOX54 News and reporter Daniel Matesevac for covering this important milestone. Watch their news segment: https://t.co/6lj5ddnRlf

Learn more about the expansion and how it strengthens U.S. supply chain resilience: https://t.co/ks6TgfBMsZ

#Biomanufacturing #SupplyChain #BioAlternatives #MadeInAmerica #MadebyManus

[Manus @manusbio]

Last week’s groundbreaking at the Manus Augusta BioFacility marked an important milestone for domestic biomanufacturing and essential-medicines production in the United States.

The new biomanufacturing facility for artemisinin – the starting material for the world’s frontline antimalarial therapy – marks the first build of a federal-private partnership.

The expansion brings new cGMP capabilities to the site, combining biomanufacturing and flow chemistry under one roof to onshore U.S. production of critical essential medicines.

“Partnerships like this one with Manus help us expand domestic manufacturing capacity and reduce reliance on overseas sources," said Wayland Coker, MBA, CSCP, Acting Deputy Director, Center for Industrial Base Management & Supply Chain, Administration for Strategic Preparedness and Response, @HHSGov @ASPRgov . “By working with industry, we can move faster and ensure critical medicines are available when Americans need them the most.”

First announced in 2024 in partnership with @HHS Administration for Strategic Preparedness and Response Industrial Base Management and Supply Chain Office (IBMSC) under the Defense Production Act Title III program, the project has since grown to $47.4 million.

Earlier this year, Manus and HHS ASPR expanded the partnership to add shikimic acid – the starting material for oseltamivir, the flu antiviral better known as Tamiflu. Manus’ bioalternatives scale-up platform has the potential to secure domestic production of more than 50 essential medicines.

We were proud to welcome Wayland Coker, Acting Deputy Director, Center for Industrial Base Management & Supply Chain, Administration for Strategic Preparedness and Response, HHS; U.S. Rep. Rick Allen, R-Ga., 12th District; U.S. Rep. Buddy Carter, R-Ga., 1st District, who made his second visit to the facility in seven months; and Augusta Mayor Garnett L. Johnson, alongside leadership from HHS ASPR’s IBMSC office, the Gates Foundation, which has previously funded Manus' artemisinin development program, and Manus’ construction and engineering partners.

Learn more about the expansion and how it strengthens U.S. supply chain resilience: https://t.co/ks6TgfBeDr

#MadebyManus #biomanufacturing #BioFacility #bioeconomy

[Manus @manusbio]

Recently, the skilled labor shortage in the U.S. has come into sharper focus. As highlighted in @thehill, the U.S. doesn’t have enough workers to meet the demands of critical industries – and that constraint poses a threat to not only economic growth, but national security as well.

That’s why programs like our new BioMADE-supported apprenticeship initiative are more important than ever.

"The biomanufacturing industry is growing, and the workforce needs to scale with it," says Christine Santos, Chief Technology Officer of Manus. This program puts apprentices directly on the plant floor, in a real production environment, and the curriculum we develop – drawing on @universityofga expertise – can serve as a blueprint for the broader industry."

Training America’s biomanufacturing workforce is critical in meeting the needs of a growing industry at scale.

At Manus we’re accelerating the transition to BioAlternatives by delivering the benefits of biomanufacturing, today.

Learn how we’re training the next generation of skilled workers to strengthen U.S. biomanufacturing: https://t.co/UqnbCh3c8Y

Help build the future of U.S. biomanufacturing. Explore careers at Manus and join us in scaling the bioeconomy: https://t.co/6Ayo2VHz7o

#BioMADE #MadebyManus #BioAlternatives #bioeconomy #biomanufacturing #workforce @TheBioMADE

[HHS ASPR @ASPRgov]

Breaking new ground! Today, we joined @manusbio’s groundbreaking event for a new facility that will bring state-of-the-art production of key starting materials for an influenza antiviral and malaria treatments to Augusta, GA.

[Manus @manusbio]

On Friday, joined by HHS leadership and members of Congress, Manus broke ground yesterday on a new domestic biomanufacturing facility for artemisinin – the starting material for the world’s frontline antimalarial therapy – at its Augusta BioFacility.

This expansion brings cGMP capabilities to the site, combining biomanufacturing and flow chemistry under one roof to onshore U.S. production of critical essential medicines.

#MadeByManus #biomanufacturing #BioAlternatives #bioeconomy

[Manus @manusbio]

Today, Manus, The BioAlternatives Company®, broke ground on a domestic biomanufacturing facility for artemisinin – the starting material for the world’s frontline antimalarial therapy – at our Augusta BioFacility.

Originally launched in 2024 through a partnership with HHS ASPR under the Defense Production Act Title III program, the federal-private collaboration has since expanded to $47.4M.

The expansion brings cGMP capabilities to the site, combining biomanufacturing and flow chemistry under one roof to onshore U.S. production of critical essential medicines.

Read the full announcement to learn how this important expansion strengthens U.S. supply chain resilience, advances biomanufacturing at scale, and has the potential to secure domestic production of more than 50 essential medicines: https://t.co/ks6TgfBMsZ

#Biomanufacturing #Bioeconomy #MadeByManus

[HHS ASPR @ASPRgov]

ASPR supports onshoring and domestic manufacturing. During a recent site visit to one facility, @manusbio GA facility, Congressional staff saw:

✅The site where key components of an influenza antiviral will be produced.
✅Ongoing domestic production of key starting materials for an anti-malaria drug.
✅Decreased dependence on foreign pharmaceutical supply chains.
✅More jobs for Americans.

Learn more about ASPR's program to make essential medicines here at home under the Defense Production Act Title III Program: https://t.co/Dmgq7r9ftb

[Manus @manusbio]

Over 80% of key ingredients in U.S. medicines are sourced overseas.

Today, we’re expanding our partnership with @HHSgov to boost U.S. production of shikimic acid – a key starting material for oseltamivir, the active ingredient in Tamiflu – helping strengthen domestic supply and reduce flu-season shortages of oseltamivir.

Read more: https://t.co/HUg7fzHYbq

#NationalSecurity #MadeInAmerica #Onshoring #SupplyChain

[Manus @manusbio]

We’re counting down to #IFTFirst 2025 in Chicago!
In just a few days, the Manus team will be at booth #S1265, ready to share our summer-ready, sugar-free treats and #sustainable, supply-secure citrus BioIngredients, Made by Manus™.
Learn more: https://t.co/62tRIUvPKl

[Manus @manusbio]

Heading to #IFTFirst 2025 next week in Chicago? Let’s connect! Manus will be at Booth #S1265 at the largest global #foodscience and innovation expo, hosted by @IFT. See you there!

[Manus @manusbio]

Industrial biotech, built to scale. This week, Manus and
@InscriptaInc united to form a new leader in biomanufacturing — delivering real-world impact through scalable bioalternatives.

Made to scale. Made to deliver. Made by Manus™
https://t.co/6xaqQSsjEB

[Manus @manusbio]

We are excited to announce that Manus has received a $32.4 million award from the @HHSGov Defense Production Act Title III Program to support the domestic production of critical essential medicines at population-scale: https://t.co/ULZuOryjay

#biotechnology #biomanufacturing

[Manus @manusbio]

We are excited to announce a strategic partnership, The Natural Sweetener Alliance, with @tateandlyleplc to expand access to natural sugar reduction solutions. Learn more about stevia Reb M, the first jointly introduced ingredient, and this partnership: https://t.co/DXzFR5evq4

[Manus @manusbio]

Last week, Manus VP of R&D, Joe Shaw, spoke at SIMB 2024. He touched on key insights and core principles behind Manus’ approach to strain design and metabolic engineering to optimize cell factories using Manus' BioOptimization Cycle™ technology: https://t.co/rduUZpTxBB

[Manus @manusbio]

Manus CTO, Christine Santos, explains our BioManufacturing Program in-depth and how it can help companies make bioalternatives at scale, enabling them to expand their scale-up and production capacity using our state-of-the-art BioFacility in Augusta: https://t.co/m65BdskOl7.

[Manus @manusbio]

The Manus team is excited to attend the @TheBioMADE 2024 Member Meeting on May 29-31 in Minneapolis, MN.

This exciting conference brings together BioMADE members and the U.S. Government to participate in member discussions about the latest trends in technology and more!

[Manus @manusbio]

While we are busy accelerating the transition to bioalternatives, we took a moment to enjoy time with our amazing team of BioHands, the beautiful weather in Augusta, and some free ice cream!

#bioeconomy #biomanufacturing #biotechnology #syntheticbiology #MadeByManus

[Manus @manusbio]

Join Manus next week as we take you behind the scenes of @SynBioBeta 2024. We’ll be connecting with key players in the industry to discuss bioalternatives and how we deliver the benefits of synthetic biology by bridging the Valley of Death between lab scale and manufacturing.

[Manus @manusbio]

Chief Technology Officer at Manus, Christine Santos, recently sat down with @SynBioBeta to discuss the potential benefits of bioalternatives, the future of synthetic biology, and how our BioManufacturing Program is helping address industry challenges: https://t.co/dXF8bnBomX